SILVER SPRING
Baxfendy cleared as first aldosterone synthase inhibitor for hypertension
- Sponsor
- AstraZeneca $AZN
- Drug
- Baxfendy · baxdrostat
- Indication
- hypertension
FDA approved AstraZeneca's Baxfendy (baxdrostat) as the first aldosterone synthase inhibitor for hypertension in combination with other antihypertensive medications.
What this means
Baxfendy is a blood pressure medication that works by blocking aldosterone production, a hormone that can cause stubborn high blood pressure. The FDA just approved Baxfendy for use alongside other blood pressure drugs in patients who need additional treatment. This gives doctors a new tool for hard-to-control hypertension by targeting a different pathway than existing medications.
Drug Watch — recent news on Baxfendy
- Baxdrostat Reduces Seated BP in Resistant Hypertension - Docwire News
- AstraZeneca's Baxfendy Set For Blockbuster Sales After Hypertension Approval - Seeking Alpha
- Targeting Aldosterone at Its Source: The Arrival of Baxdrostat for Resistant Hypertension - Pharmacy Times – Pharmacy Practice News and Expert Insights
- Second-generation aldosterone synthase inhibitors (baxdrostat, lorundrostat, dexfadrostat phosphate, vicadrostat) suppress aldosterone while maintaining cortisol biosynthesis, with early-phase reductions in blood pressure and albuminuria in resistant hypert - Vera Health
- Second-generation aldosterone synthase inhibitors (baxdrostat, lorundrostat, dexfadrostat phosphate, vicadrostat) suppress aldosterone while maintaining cortisol biosynthesis, with early-phase reductions in blood pressure and albuminuria in resistant hypert - Vera Health
Sponsor Watch — recent news on AstraZeneca
- Cathie Wood Just Bet Big on This Biotech Stock
- Is NeoGenomics (NEO) Undervalued After Its FDA Approved PTEN Test Launch?
- The First Oral Cholesterol Pill Is Here. Which of These 5 Stocks Benefits Most?
- MSD wins FDA approval for cholesterol pill to help plug Keytruda void
- Merck Stock Rises After U.S. Approval for Powerful Cholesterol-Cutting Pill